Molecular diagnosis has unlocked several opportunities in the medical sector. It is the most innovative way to identify a disease at a molecular level including DNA, RNA, and proteins in fluid and tissue.
Asia-Pasific Oncology Molecular Diagnostic Outlook:
Molecular diagnosis has unlocked several opportunities in the medical sector. It is the most innovative way to identify a disease at a molecular level including DNA, RNA, and proteins in fluid and tissue. For this, several tools are used to identify specific sequences of RNA or DNA that might be associated with several diseases including deletions, single nucleotide polymorphism, rearrangements, and insertions.
Over the years, we have increased over the understanding of the human genome, thanks to advancements in the ability to sequence proteins, RNA, and DNA. It has opened a whole new branch of medicine that can focus solely on genetic abnormalities and molecular derangements of tumors. This drastic development has the potential to change diagnostic categories, enable early detection and prevention, and increase treatment strategies, along with improving outcomes for cancer patients. Moreover, the advent of molecular diagnostics in oncology has helped take one more step toward developing precision medicine.
According to Allied Market Research, the Asia-Pacific oncology molecular diagnostics market is expected to reach $732 million by 2026, growing at a CAGR of 9.0% from 2019 to 2026. Increase in prevalence of various types of cancers, growth in biomarker identification, and surge in funding by government bodies have boosted the growth of the market.
The applications of molecular diagnostics are limitless, especially in clinical oncology. The mutation analysis can be used for hereditary benefits including various preventive interventions and tight medical surveillance.
Request for Sample Report for More Insights@ https://www.alliedmarketresearch.com/request-sample/6652
Cancers caused due to germ-line mutations need significant medication or treatment strategy. In addition, personalized selection of cancer drugs on the basis of actionable mutations is an instrumental part of cancer therapy. Thus, molecular diagnostics plays a vital part to develop targeted drugs.
Extensive research suggests that target-based agents are active in molecularly selected populations of patients, which makes the identification of predictive biomarkers mandatory for the clinical development of novel drugs. To be precise, mutations of epidermal growth factor receptor (EGFR) or rearrangements of the ALK gene in non-small-cell lung cancer are perfect examples of predictive biomarkers for treatment with specific inhibitors. Thus, the introduction of molecular diagnostics in oncology would help increase the chances of identifying molecular targets in several cancer patients and also allow us to understand the evolution of the disease during the course of treatment. What’s more, molecular diagnostics in oncology could be the key to developing personalized medicine for patients with rare cancers.
Top Leading Players:
- Abbott Laboratories
- Biomérieux Sa
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers
- Danaher (Cepheid)
- Diasorin Spa
- Illumina Inc.
- Agilent Technologies Inc.
- Sysmex Corporation
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com